FAP
Fibroblast activation protein
Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components. FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma.
All Product Categories
-
FAP Related Products (84)
Related Products (84)
-
Antibodies (4)
-
DOTAGA.(SA.FAPi)2 analogue TFA
0 ImagesCat. No.: HY-164364BPurity: 99.38%DOTAGA.(SA.FAPi)2 analogue TFA is a DOTAGA.(SA.FAPi)2 TFA (HY-164364A) analogue, in which the ligand and the chelator are identical to those of DOTAGA.(SA.FAPi)2 TFA. DOTAGA.(SA.FAPi)2 TFA is a potent dimeric fibroblast-activation protein inhibitor (FAPi).
-
GFAP/NF-κB/APOE/NLRP3-IN-1
0 ImagesCat. No.: HY-183796GFAP/NF-κB/APOE/NLRP3-IN-1 is an orally active, blood-brain barrier-permeable multi-target inhibitor with an IC50 of 3.50 nM against Acetylcholinesterase. GFAP/NF-κB/APOE/NLRP3-IN-1 inhibits BACE-1 with an IC50 of 14.61 nM. GFAP/NF-κB/APOE/NLRP3-IN-1 inhibits Aβ1-42 aggregation with an IC50 of 8.63 μM. GFAP/NF-κB/APOE/NLRP3-IN-1 reduces the levels of GFAP, NLRP3 inflammasome, NF-κB and APOE. GFAP/NF-κB/APOE/NLRP3-IN-1 is applicable for the research of Alzheimer's disease and neuroblastoma.
-
DOTAGA.Glu.(FAPi)2
0 ImagesCat. No.: HY-159768ACAS No.: 2882922-68-9DOTAGA.Glu.(FAPi) 2 is a FAPI homodimer in which a central glutamic acid (Glu) linker connects FAPI and a chelator. Radiolabeled with gallium-68, lutetium-177 or terbium-161, DOTAGA.Glu.(FAPi) 2 is applicable to FAP-positive cancer PET imaging studies. DOTAGA.Glu.(FAPi) 2 is suitable for research related to prostate adenocarcinoma and recurrent glioblastoma multiforme.
-
FAPI-2 TFA
0 ImagesCat. No.: HY-128642APurity: 99.40%
-
SB03178
0 ImagesCat. No.: HY-161262CAS No.: 2952588-12-2
-
FAP-IN-1
0 ImagesCat. No.: HY-149860CAS No.: 2956858-96-9
-
FAP-IN-9
0 ImagesCat. No.: HY-182272FAP-IN-9 (compound P12) is a fibroblast activation protein (FAP) inhibitor with an IC50 of 0.38 nM against human FAP. FAP-IN-9 functionally inhibits FAP activity, and its specific binding is verified by in vitro and in vivo blocking assays. FAP-IN-9 forms stable complexes and acts as a tumor-targeting agent. When labeled with 99mTc, FAP-IN-9 serves as a SPECT probe and is applicable to research related to glioblastoma.
-
QI-18
0 ImagesCat. No.: HY-159934CAS No.: 3093894-38-0QI-18 is a fibroblast activation protein (FAP) inhibitor with the IC50 of 0.50 nM, which is a 6.5-fold increase in potency over that of UAMC-1110 (HY-100684，IC50 of 3.25 nM). QI-18 can be used to synthesize high tumor selectivity and high dose radiotracers for the diagnosis and study of tumors.
-
FAPI-JNU
0 ImagesCat. No.: HY-174421FAPI-JNU is a molecule targeting fibroblast activation protein (FAP). FAPI-JNU specifically binds to FAP highly expressed in the tumor microenvironment, and uses radionuclides [68Ga]Ga or [177Lu]Lu to achieve tumor imaging diagnosis. [177Lu]Lu−FAPI−JNU can effectively target and inhibit tumor growth in tumor-bearing mice. FAPI-JNU is promising for research of FAP-positive tumors (such as various solid tumors).
-
CL 118326
0 ImagesCat. No.: HY-182434CAS No.: 97012-61-8CL 118326 is a potent, selective, competitive inhibitor of mammalian pancreatic phospholipase A2 (PLA2) and a weak antagonist of platelet-activating factor receptor (PAF receptor). CL 118326 competitively inhibits mammalian pancreatic PLA2 (porcine: IC50 = 1.55 μg/mL), and shows no activity against snake venom or bee venom PLA2. CL 118326 inhibits PAF-induced and thrombin-induced platelet aggregation, as well as the release of leukotriene (LTC4) and histamine from basophil-enriched leukocytes. CL 118326 can be used for research on inflammation and allergic reactions.
-
Fas C-Terminal Tripeptide
0 ImagesCat. No.: HY-103323CAS No.: 189109-90-8Fas C-Terminal Tripeptide is a C-terminal tripeptide of Fas. Fas C-Terminal Tripeptide shows the inhibitory effect on Fas/FAP-1 binding.
